Therapeutic | Ofatumumab |
Target | MS4A1 |
Heavy Chain | EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK |
100% seqID Fv Structure | 3giz [Fvs: HL], 6y92 [Fvs: CD, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3giz [Fvs: HL] |
100% seqID Structure | 6y92 [Fvs: CD, HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (Aug '24) | Approved |
Estimated Status (Aug '24) | Active |
Recorded Developmental Technology | Medarex HuMAb Mouse |
INN Year Proposed | 2005 |
INN Year Recommended | 2006 |
Companies Involved | Genmab, GlaxoSmithKline, Mundipharma International, National Cancer Centre (Singapore), Novartis, Roswell Park Cancer Institute, University Health Network |
Conditions Approved | Chronic lymphocytic leukaemia |
Conditions Active | B-cell lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Multiple sclerosis, Marginal zone B-cell lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma |
Conditions Discontinued | Neuromyelitis optica, Pemphigus vulgaris, Rheumatoid arthritis, Waldenstrom's macroglobulinaemia |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]